Ankyra Welcomes New Directors to Enhance Leadership
Ankyra is excited to announce the recent appointment of two outstanding individuals, Dr. Julia G. Butchko and Ms. Tara Withington, to its Board of Directors. Expanding the board to seven members is a significant step during an important time in the company’s growth.
Board Excitement
Tillman Gerngross, PhD, the Chairman of the Board, shared his enthusiasm, stating, "We are pleased to welcome Dr. Butchko and Ms. Withington to the Board. These impressive individuals bring fresh insights to Ankyra as we navigate a crucial phase in the company's expansion." The addition of these leaders reflects a commitment to innovation and strategic advancement, especially following previous successes.
Insights from the Newly Appointed Board Members
Dr. Julia G. Butchko brings a wealth of experience, having dedicated 25 years to the biopharmaceutical industry. She previously worked as the Chief Development Officer at Immunovant (NASDAQ: IMVT), where she significantly advanced therapies for autoimmune diseases. Her impressive background includes leadership roles at Eli Lilly, along with a strong academic foundation from prestigious institutions.
Dr. Butchko expressed her excitement about joining Ankyra during this transformative period, saying, "This year is set to be impactful for the company as we grow the ANK-101 Phase 1 program. I believe Ankyra’s innovative technology has tremendous potential to improve cancer treatments." Her insights are expected to be crucial as the company seeks new solutions in oncology.
Tara Withington's Background
Ms. Tara Withington comes with over 40 years of executive experience in the nonprofit sector. Currently, she is Vice President with Executive Director, Incorporated, where she has a strong track record of promoting organizational excellence. Her leadership in managing various scientific organizations illustrates her ability to navigate complex challenges while supporting essential missions.
Withington shared her enthusiasm about joining Ankyra's board, emphasizing her dedication to improving patient experiences through innovative treatments. "Immunotherapy offers opportunities for lasting responses and enhanced patient experiences, and I align with Ankyra’s vision of delivering new drugs for cancer patients while ensuring access for all who may need them," she remarked.
Dedication to Patient-Centered Solutions
Dr. Howard L. Kaufman, President and CEO of Ankyra, highlighted the significant value these new board members bring, emphasizing their expertise in advancing research and development with a focus on patients. Ankyra's flagship asset, ANK-101, which targets IL-12 therapy, has successfully entered phase I clinical trials, treating patients with advanced solid tumors at several study sites across North America.
This strategic appointment aligns Ankyra with the growing demand for innovative cancer therapies, empowering the company to fulfill its mission more effectively. With the board transitioning, the combination of talents and backgrounds will substantially influence Ankyra's trajectory and impact within the biotechnology sector.
About Ankyra Therapeutics
Ankyra Therapeutics is an innovative biotechnology company focused on developing new cancer treatments. Utilizing its unique technology platform, Ankyra aims to significantly enhance the therapeutic window of cytokine drugs. This platform establishes a stable depot within tumors, allowing for prolonged immune activation while reducing systemic toxicity. Founded in 2019 and based in Cambridge, Massachusetts, Ankyra is positioned for meaningful innovations in cancer treatment as the company advances.
Frequently Asked Questions
What roles will Dr. Butchko and Ms. Withington fulfill?
They will serve as independent board members, bringing their expertise to help shape Ankyra's strategic direction.
How does Ankyra's technology benefit cancer therapies?
Ankyra’s platform enhances the delivery and effectiveness of cytokine drugs, resulting in more effective cancer treatments with fewer side effects.
What is the significance of the ANK-101 program?
ANK-101 represents a major advancement in targeted cancer therapy, currently in phase I trials to evaluate its effectiveness in patients with advanced solid tumors.
What experiences do Ms. Withington and Dr. Butchko bring to Ankyra?
Ms. Withington offers extensive experience in nonprofit management, while Dr. Butchko brings deep expertise in biopharmaceutical research and development.
When did Ankyra Therapeutics get founded?
Ankyra Therapeutics was founded in 2019, focusing on innovative approaches to cancer treatment.
